184 related articles for article (PubMed ID: 38679739)
1. Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients.
Pérez Compte D; Etourneau L; Hesse AM; Kraut A; Barthelon J; Sturm N; Borges H; Biennier S; Courçon M; de Saint Loup M; Mignot V; Costentin C; Burger T; Couté Y; Bruley C; Decaens T; Jaquinod M; Boursier J; Brun V
Biomark Res; 2024 Apr; 12(1):44. PubMed ID: 38679739
[TBL] [Abstract][Full Text] [Related]
2. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.
Verschuren L; Mak AL; van Koppen A; Özsezen S; Difrancesco S; Caspers MPM; Snabel J; van der Meer D; van Dijk AM; Rashu EB; Nabilou P; Werge MP; van Son K; Kleemann R; Kiliaan AJ; Hazebroek EJ; Boonstra A; Brouwer WP; Doukas M; Gupta S; Kluft C; Nieuwdorp M; Verheij J; Gluud LL; Holleboom AG; Tushuizen ME; Hanemaaijer R
Nat Commun; 2024 May; 15(1):4564. PubMed ID: 38811591
[TBL] [Abstract][Full Text] [Related]
4. Predictive plasma biomarker for gestational diabetes: A case-control study in China.
Chen F; Li M; Fei X; Chen X; Zhang Z; Zhu W; Shen Y; Mao Y; Liu J; Xu J; Du J
J Proteomics; 2023 Jan; 271():104769. PubMed ID: 36372392
[TBL] [Abstract][Full Text] [Related]
5. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.
Sakane S; Hikita H; Shirai K; Sakamoto T; Narumi R; Adachi J; Kakita N; Yamada Y; Toyoda H; Takahashi H; Suda G; Kai M; Tahata Y; Sakamori R; Kumazaki S; Fukumoto K; Myojin Y; Murai K; Kodama T; Tatsumi T; Tomonaga T; Sakamoto N; Morii E; Takehara T
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829196
[TBL] [Abstract][Full Text] [Related]
7. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study.
Gleissner CA; Erbel C; Linden F; Domschke G; Akhavanpoor M; Helmes CM; Doesch AO; Kleber ME; Katus HA; Maerz W
Atherosclerosis; 2017 May; 260():121-129. PubMed ID: 28390290
[TBL] [Abstract][Full Text] [Related]
9. Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus.
Faustini F; Idborg H; Fuzzi E; Larsson A; Lie WR; Pötzsch S; Okitsu SL; Svenungsson E; Gunnarsson I
Lupus; 2023 Feb; 32(2):252-262. PubMed ID: 36508734
[TBL] [Abstract][Full Text] [Related]
10. Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients.
Dabbah S; Ben Yakov G; Kaufmann MI; Cohen-Ezra O; Likhter M; Davidov Y; Ben Ari Z
Minerva Gastroenterol (Torino); 2023 Oct; ():. PubMed ID: 37889111
[TBL] [Abstract][Full Text] [Related]
11. Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
Fan R; Yu N; Li G; Arshad T; Liu WY; Wong GL; Liang X; Chen Y; Jin XZ; Leung HH; Chen J; Wang XD; Yip TC; Sanyal AJ; Sun J; Wong VW; Zheng MH; Hou J
Liver Int; 2024 Mar; 44(3):749-759. PubMed ID: 38131420
[TBL] [Abstract][Full Text] [Related]
12. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
13. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T
Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology.
Gleissner CA; Erbel C; Linden F; Domschke G; Akhavanpoor M; Doesch AO; Buss SJ; Giannitsis E; Katus HA; Korosoglou G
Atherosclerosis; 2016 Aug; 251():94-100. PubMed ID: 27295060
[TBL] [Abstract][Full Text] [Related]
15. Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT.
Lee J; Byrne CJ; Brennan PN; MacPherson I; Dow E; Dillon JF
Ann Hepatol; 2024; 29(2):101280. PubMed ID: 38219950
[TBL] [Abstract][Full Text] [Related]
16. Polymeric immunoglobulin receptor and galectin-3-binding protein are raised in biliary atresia: Reveals a proteomic-based study.
Ram AK; Kanojia RP; Bhatia A; Menon P; Minz RW; Dhawan V; Arora A; Kumar Y
J Proteomics; 2023 Sep; 287():104974. PubMed ID: 37467891
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Serum Galectin-3 Binding Protein Level in Patients with Pulmonary Arterial Hypertension.
Li M; Pan W; Tian D; Chen D; Zhang X; Zhang Y; Chen S; Zhou D; Ge J
Curr Vasc Pharmacol; 2024; 22(1):67-77. PubMed ID: 38038005
[TBL] [Abstract][Full Text] [Related]
18. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
[TBL] [Abstract][Full Text] [Related]
19. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
[TBL] [Abstract][Full Text] [Related]
20. Association of Serum Galectin-3-Binding Protein and Metabolic Syndrome in a Chinese Adult Population.
Zhen S; Cai R; Yang X; Ma Y; Wen D
Front Endocrinol (Lausanne); 2021; 12():726154. PubMed ID: 34858323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
